Aims This analysis aims to evaluate the budget impact of intravenous iron therapy with ferric carboxymaltose for patients with systolic chronic heart failure and iron deficiency, from the perspective of the French public health insurance. Methods and results A budget impact model was adapted to forecast the budget impact over 5 years, according to two scenarios: one where patients receive ferric carboxymaltose according to market share forecast and another where patients are not treated for iron deficiency. Clinical data were extrapolated from pooled data from four randomized controlled trials. The time horizon was extended to 5 years by applying transition probabilities estimated from the CONFIRM‐HF trial. Epidemiological parameters for France were derived from the literature. Cost parameters were derived from national available databases. In the base case analysis, the modelled 5 year cost difference between the scenarios with ferric carboxymaltose vs. no iron deficiency treatment in a population of 189 334 prevalent and incident patients led to €0.8m savings. The cumulative savings resulted from a reduction in the hospitalization costs associated with worsening heart failure (€−35.8m) as well as a reduction in the follow‐up costs (€−2.9m). These cost savings outweighed the costs of ferric carboxymaltose treatment (€37.7m). Sensitivity analyses showed that the budget impact varied from €−34m to €+146m. Parameters with the most impact on the budget were the hospitalization rate for patients not treated for iron deficiency, the number of ambulatory sessions needed, the absence of hospitalization cost differentiation between New York Heart Association classes, and administration settings costs. Conclusions Iron deficiency treatment with ferric carboxymaltose in systolic chronic heart failure patients results in an improvement of New York Heart Association class and thereby increases the well‐being of the patients, while providing an overall cost saving for the French national health insurance.

No abstract

inhibitor have been calculated over 3-years and compared for the two scenario analyses. Emicizumab price was assumed equal to 210.2V/mg in order to have the same annual costs of aPCC prophylaxis. Sensitivity analyses were performed to identify the price scenario where emicizumab reported a neutral budget impact. RESULTS: Based on actual treatment utilization data in Italy, the model estimated a 3-years overall cost of 368,839V mln in all hemophilic patients with inhibitor (mean cost per patient/ year ¼723,213V). Assuming a possible switch also from less expensive regimens (on-demand and high dose rFVIII prophylaxis) to emicizumab prophylaxis, a budget impact of +38.5Vmln (+10%) was reported over three-years. Changing emicizumb price, a neutral budget impact was obtained at 157.6V/mg (-25% of basecase price). CONCLUSIONS: The budget estimation is sensitive to emicizumab price. A neutral budget impact can be obtained if emicizumab price was set to 157.6V/mg. Below the neutral price, emicizumab prophylaxis use could save millions of euro. For example, an expected budgetary saving of 39.0V mln was estimated assuming a price of 105.10V/mg.

No abstract

chart review study of patients aged 1-12 years with a primary varicella diagnosis between 2011 and 2015. Healthcare resource utilization (HCRU) associated with varicella, unit costs, and work loss were used to estimate direct and indirect costs. All costs are presented in 2015 Polish Zloty (PLN) / Euros (€ ). Results: 150 children with varicella were included (75 outpatients, 75 inpatients), with a mean age of 3.9 (SD: 2.6) and 4.2 (SD: 2.3) years, respectively. One or more complications were experienced by 14.7% of outpatients and 82.7% of inpatients, the most common being skin and soft tissue infections, dehydration, pneumonia, and cerebellitis. HCRU estimates included use of over-the-counter (OTC) medications (80.0% outpatients, 81.3% inpatients), prescription medications (80.0% outpatients, 93.3% inpatients), tests/procedures (0.0% outpatients, 69.3% inpatients), and consultation with allied health professionals (0.0% outpatients, 24.0% inpatients). The average duration of hospital stay was 4.7 (95% CI: 4.1 , 5.3) days for inpatients. The total combined direct and indirect cost per varicella case was 5013.3 PLN / € 1,198.1, for inpatients and 1027.2 PLN/ € 245.5, for outpatients. The overall annual cost of varicella in Poland for children aged 1-15 years in 2015 was estimated at 177,655,759.6 PLN,/€ 42,458,716.0. ConClusions: Varicella is associated with substantial clinical burden in Poland, resulting in the utilization of a significant amount of healthcare resources.